| 摘要 |
1. Claims (for the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE) Pyrrolo[3,4-d][2]benzazepine derivatives of the general formula see diagramm : EP0094668,P27,F1 wherein R1 and R3 signify hydrogen, (C1 -C7 )-alkyl, hydroxy, (C1 -C7 )-alkoxy or the group -OCOR', R' signifies hydrogen (C1 -C6 )-alkyl or phenyl and R2 and R4 signify hydrogen or R1 and R2 and/or R3 and R4 together signify oxo groups, with the proviso that at least one oxo group is present, R signifies hydrogen, (C1 -C7 )-alkyl, hydroxy-(C2 -C7 )-alkyl, amino-(C2 -C7 )-alkyl, mono- or di-(C1 -C7 )-alkylamino-(C2 -C7 )-alkyl or the group -(C1 -C6 )-alkyl-COR**21 , R**21 signifies hydroxy, (C1 -C7 )-alkoxy, amino or mono- or di-(C1 -C7 )-alkylamino, R5 signifies halogen with an atomic number not exceeding 35 or hydrogen and R6 signifies halogen with an atomic number not exceeding 35, with the proviso that R signifies (C1 -C7 )-alkyl or hydrogen when R1 or R3 signifies hydroxy, (C1 -C7 )-alkoxy or -OCOR', the N-oxides and the pharmaceutically acceptable salts thereof. 1. Claims (for the Contracting State AT) A process for the manufacture of pyrrolo[3,4-d][2]benzazepine derivatives of the general formula see diagramm : EP0094668,P29,F2 wherein R1 and R3 signify hydrogen, (C1 -C7 )-alkyl, hydroxy, (C1 -C7 )-alkoxy or the group -OCOR', R' signifies hydrogen, (C1 -C6 )-alkyl or phenyl and R2 and R4 signify hydrogen or R1 and R2 and/or R3 and R4 together signify oxo groups, with the proviso that at least one oxo group is present, R signifies hydrogen, (C1 -C7 )-alkyl, hydroxy-(C2 -C7 )-alkyl, amino-(C2 -C7 )-alkyl, mono- or di-(C1 -C7 )-alkylamino-(C2 -C7 )-alkyl or the group -(C1 -C6 )-alkyl-COR**21 , R**21 signifies hydroxy, (C1 -C7 )-alkoxy, amino or mono- or di-(C1 -C7 )-alkylamino, R5 signifies halogen with an atomic number not exceeding 35 or hydrogen and R6 signifies halogen with an atomic number not exceeding 35, with the proviso that R signifies (C1 -C7 )-alkyl or hydrogen when R1 or R3 signifies hydroxy, (C1 -C7 )-alkoxy or -OCOR', of N-oxides and of pharmaceutically acceptable salts thereof, characterized by a) for the manufacture of compounds of formula I above in which R1 or R3 signifies hydrogen or (C1 -C7 )-alkyl and the remaining symbols have the above significance and of N-oxides thereof, oxidizing a compound of the general formula see diagramm : EP0094668,P30,F1 wherein one of R11 and R31 signifies hydrogen and the other signifies hydrogen or (C1 -C7 )-alkyl and R, R5 and R6 have the above significance, with a peracid, or b) for the manufacture of compounds of formula I above in which R1 or R3 signifies hydroxy and the remaining substituents have the above significance or R1 and R3 and R4 in each case together signify oxo groups and the remaining symbols have the above significance, oxidizing a compound of formula I in which R1 or R3 signifies hydrogen and the remaining substituents have the above significance or a compound of formula II above in which R11 and R31 signify hydrogen with a lead (IV) carboxylate in the presence of a strong acid, or c) for the manufacture of compounds of formula I above in which R1 or R3 signifies acetoxy and the remaining substituents have the above significance, treating a compound of formula I in which R1 or R3 signifies hydrogen and the remaining substituents have the above significance or a compound of formula II above in which R11 and R31 signify hydrogen with lead tetraacetate in acetic acid, or d) for the manufacture of compounds of formula I above in which R1 or R3 signifies -OCOR' and the remaining substituents have the above significance, treating a compound of formula I in which R1 or R3 signifies hydroxy and the remaining substituents have the above significance with a carboxylic acid anhydride in the presence of a base, or e) for the manufacture of compounds of formula I above in which R1 or R3 signifies (C1 -C7 )-alkoxy and the remaining substituents have the above significance, treating a compound of formula I in which R1 or R3 signifies -OCOR' or hydroxy and the remaining substituents have the above significance or a compound of the formula see diagramm : EP0094668,P30,F2 wherein R12 signifies acetoxy and R, R5 and R6 have the above significance, with a (C1 -C7 )-alkanol in the presence of a strong acid, or f) for the manufacture of compounds of formula I above in which R1 or R3 signifies hydrogen or (C1 -C7 )-alkyl and the remaining substituents have the above significance, desoxidizing an N-oxide of the general formula see diagramm : EP0094668,P31,F1 wherein R, R1 , R2 , R3 , R4 , R5 and R6 have the above significance, and, if desired, g) converting a compound of formula I into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable salt of a compound of formula I into another pharmaceutically acceptable salt. |
